David L. Johnson
David L. Johnson is the President and CEO of BioCrossroads. In December 2012, he was elected President and CEO of the Central Indiana Corporate Partnership (CICP), a regional strategic collaboration of business leaders and university presidents.
Johnson has been engaged with CICP for more than a decade as one of the original organizers and chief executive of BioCrossroads, a market-based enterprise focused on collaboration and strategic investments for growing Indiana’s life sciences sector. Among its many activities, BioCrossroads informs and educates; raises and invests venture capital funds in promising new companies; and builds business collaborations by bridging gaps across academia and industry. Through his work at BioCrossroads, Johnson has been responsible for raising over $300 million dollars in philanthropic, corporate and venture capital funding to advance new companies, promote innovative research, and deliver on the promise of highly skilled 21st-Century employment opportunities for Hoosiers.
He had previously been a partner in the Indianapolis-based law firm of Baker & Daniels for nearly 20 years where he advised corporate and public sector clients on issues of economic development, public and project financing and capital formation.
Johnson is an honors graduate of Harvard University, Harvard Law School and Oxford University, where he studied as a Rhodes Scholar.
Nora Doherty joined BioCrossroads in 2003 after working many years with entrepreneurial companies. She is vice president of finance for BioCrossroads and managing director for its Seed Funds. In this role, she serves on the Board of Directors of portfolio companies including FAST, SonarMed, and Grest among others. Doherty also supports other program-related activities.
Doherty has a history of working for entrepreneurial companies. She was vice president of Electronic Evolutions and a co-founder, vice president of Operations and vice president Legal, Human Resources and Administration, and corporate secretary with Escient Technologies. Escient Technologies managed numerous consumer electronic and internet related businesses, including Gracenote® which was purchased by Sony in 2008.
Doherty received her BA and MBA from Indiana University, where she was a member of the honors program. She also received the "Excellence in Leadership" award as special recognition from the professors and administration of Indiana University MBA-CIP for leadership and contribution to the program.
Troy Hege serves as Director of Projects for BioCrossroads. In this role Hege works to vet, develop and manage emergent life science opportunities. Currently, Hege directly supports BioCrossroads’ efforts related to Indiana Biosciences Research Institute and the Indiana Health Information Exchange (IHIE) and also works closely with the Indiana Clinical Translational Sciences Institute at the Indiana University Medical Center. Hege also serves as an advisor to the Indiana Seed Fund II and assists the fund manager in deal sourcing, diligence and execution of portfolio investments.
Hege serves on the boards of directors for Diagnotes Inc., a clinical communications technology platform, Thrive Inc., a clinical data repository and analytics platform, and the Datalys Center, a sports medicine research institute formed in collaboration with the National Collegiate Athletic Association and the American College of Sports Medicine.
Prior to joining BioCrossroads, Hege spent seven years in management consulting working for consulting firms in Boston and New York, where he advised leading healthcare, pharmaceutical and technology companies in brand management, business development and technology strategy. Hege received his BS degree from Purdue University and MBA from Harvard Business School.
As Project Director for BioCrossroads, a non-profit organization advancing Indiana’s life sciences industry, Stemme is responsible for identifying and developing opportunities for collaboration between Indiana’s life sciences companies and research universities. In this role, Stemme manages BioCrossroadsLINX, an initiative focused on leveraging Indiana’s strengths in pharmaceutical development and manufacturing. He also serves as a key contributor to BioCrossroads’ market research division, BioIntellex, drafting reports on Indiana’s contract drug development, medical device and health information technology sectors. He supports the State’s economic development agency by providing market information to attract and grow life sciences companies in Indiana and serves as an advisor to Indiana Seed Fund II, assisting the fund manager in deal sourcing, diligence and execution of portfolio investments. He currently serves on the boards of Aarden Pharmaceuticals, AgeneBio and Muroplex Therapeutics.
Prior to joining BioCrossroads in 2005, Stemme was employed by Eli Lilly and Company as a Senior Associate in the company’s Corporate Affairs group, where he ran the company’s political action committee. He also worked as a Financial Analyst in the company’s biotechnology unit and was a member of the team that established Lilly Systems Biology, Ltd. in Singapore. Previously, Stemme was a Manager in Arthur Andersen’s Assurance practice, providing audit and tax consulting to companies in the energy, software and healthcare industries.
Stemme currently serves in a number of volunteer community roles, including the Bloomington Life Sciences Partnership Advisory Board and Special Projects Council for The Children’s Museum of Indianapolis. In 2002, Stemme was one of 25 Indianapolis leaders selected to participate in the Stanley K. Lacy Executive Leadership Series. He holds a degree in Accounting from Butler University in Indianapolis, where he has served as President of the University’s Alumni Association and was a member of the Board of Trustees.
Lori LeRoy is the Vice President of Communications for BioCrossroads and also serves in the same role at the Central Indiana Corporate Partnership, an organization that includes the chief executives of Central Indiana’s prominent corporations and university presidents in a strategic and collaborative effort dedicated to the region’s continued prosperity and growth. BioCrossroads is CICP's sector initiative for the life sciences. She leads all public relations, marketing, advertising, and event development for both organizations.
LeRoy was previously marketing manager, communications for Roche Diagnostics Diabetes Care business area. She was also a public relations consultant at Roche where she managed product public relations for its laboratory, hospital, physician’s office and research products. With a strong background in consumer PR, brand awareness campaigns and health care/technology PR, she has also held positions as senior manager, corporate communications at Philips Consumer Electronics and corporate communications manager at AirTran Airways.
She earned a B.A. in English and Asian Studies from Oglethorpe University in Atlanta, where she also served as a member of the Alumni Association Board of Directors.
Julie Routt is BioCrossroads’ office manager. Julie has been with BioCrossroads since 2003. Prior to joining the organization, Julie worked at the Indy Partnership, the Indianapolis Mayor’s Office, and the Indianapolis Zoo. She is a graduate of Tri-State University in Angola, Indiana.
Brenda Bratton joined BioCrossroads in January 2005 as Executive Assistant for David Johnson, President and CEO. Previously she worked at the law firm of Baker & Daniels for 15 years.